Discover open access scientific publications

Search, annotate, share and cite publications

Publications by J. Naidoo

MA05.02 PACIFIC Subgroup Analysis: Pneumonitis in Stage III, Unresectable NSCLC Patients Treated With Durvalumab vs. Placebo After CRT

Journal of Thoracic Oncology

English

632 Cutaneous Immune-Related Adverse Events in 1,857 Patients Treated With Anti-Pd-1 Therapy at an Academic Center

Journal of Investigative Dermatology

English

Related publications

PL02.01 Overall Survival With Durvalumab Versus Placebo After Chemoradiotherapy in Stage III NSCLC: Updated Results From PACIFIC

Journal of Thoracic Oncology

English

Brief Report: Three-Year Overall Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC - Update From PACIFIC

Journal of Thoracic Oncology

English

P1.01-88 Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFRm-Positive Stage III NSCLC (LAURA)

Journal of Thoracic Oncology

English

Q-TWiST Analysis Comparing Ipilimumab/Dacarbazine vs Placebo/Dacarbazine for Patients With Stage III/IV Melanoma

British Journal of Cancer

Cancer Research

Oncology

2013

English

MA05.01 E6508: Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Unresectable Stage III NS-NSCLC

Journal of Thoracic Oncology

English

P2.01-58 Demographics, Clinical Characteristics and Treatment Sequencing in Stage III Unresectable NSCLC Patients: A Cancerlinq Cohort

Journal of Thoracic Oncology

English

P1.16-01 Prognostic Variables Associated With Improved Outcomes in Stage III NSCLC Patients Treated With Consolidation Pembrolizumab

Journal of Thoracic Oncology

English

OA01.07 Updated Results of a Phase II Trial of Concurrent Chemoradiation With Consolidation Pembrolizumab in Patients With Unresectable Stage III NSCLC

Journal of Thoracic Oncology

English

Predictive and Prognostic Role of Metabolic Response in Patients With Stage III NSCLC Treated With Neoadjuvant Chemotherapy

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by J. Naidoo

MA05.02 PACIFIC Subgroup Analysis: Pneumonitis in Stage III, Unresectable NSCLC Patients Treated With Durvalumab vs. Placebo After CRT

632 Cutaneous Immune-Related Adverse Events in 1,857 Patients Treated With Anti-Pd-1 Therapy at an Academic Center

Related publications

PL02.01 Overall Survival With Durvalumab Versus Placebo After Chemoradiotherapy in Stage III NSCLC: Updated Results From PACIFIC

Brief Report: Three-Year Overall Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC - Update From PACIFIC

P1.01-88 Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFRm-Positive Stage III NSCLC (LAURA)

Q-TWiST Analysis Comparing Ipilimumab/Dacarbazine vs Placebo/Dacarbazine for Patients With Stage III/IV Melanoma

MA05.01 E6508: Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Unresectable Stage III NS-NSCLC

P2.01-58 Demographics, Clinical Characteristics and Treatment Sequencing in Stage III Unresectable NSCLC Patients: A Cancerlinq Cohort

P1.16-01 Prognostic Variables Associated With Improved Outcomes in Stage III NSCLC Patients Treated With Consolidation Pembrolizumab

OA01.07 Updated Results of a Phase II Trial of Concurrent Chemoradiation With Consolidation Pembrolizumab in Patients With Unresectable Stage III NSCLC

Predictive and Prognostic Role of Metabolic Response in Patients With Stage III NSCLC Treated With Neoadjuvant Chemotherapy